Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom

INTRODUCTION: The glucagon-like peptide-1 receptor agonists liraglutide and lixisenatide are effective at reducing glycated hemoglobin (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM). Although liraglutide has demonstrated superior efficacy in head-to-head clinical trials, real-world...

Descripción completa

Detalles Bibliográficos
Autores principales: Feher, Michael, Vega-Hernandez, Gabriela, Mocevic, Emina, Buysse, Brian, Myland, Melissa, Power, Geraldine S., Nystrup Husemoen, Lise L., Kim, Joseph, Witte, Daniel R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380503/
https://www.ncbi.nlm.nih.gov/pubmed/28281244
http://dx.doi.org/10.1007/s13300-017-0241-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380503/
https://www.ncbi.nlm.nih.gov/pubmed/28281244
http://dx.doi.org/10.1007/s13300-017-0241-z

Ejemplares similares